Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Sells 11,447 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $7.66, for a total value of $87,684.02. Following the transaction, the director now owns 7,229,861 shares in the company, valued at approximately $55,380,735.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.82, for a total value of $100,962.54.
• On Tuesday, March 19th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.79, for a total value of $216,382.66.
• On Tuesday, March 5th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.06, for a total value of $241,851.24.
• On Tuesday, February 20th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $12.32, for a total value of $247,065.28.
• On Tuesday, February 6th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.30, for a total value of $106,457.10.
• On Tuesday, January 23rd, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.58, for a total value of $212,171.32.

Recursion Pharmaceuticals Trading Down 0.9 %

RXRX traded down $0.07 on Thursday, hitting $7.40. 2,860,086 shares of the company were exchanged, compared to its average volume of 6,626,345. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.54 and a twelve month high of $16.75. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -4.77 and a beta of 0.76. The firm has a 50-day moving average price of $10.84 and a two-hundred day moving average price of $9.10.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06. The company had revenue of $10.89 million during the quarter, compared to the consensus estimate of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on RXRX. KeyCorp lifted their price objective on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. TD Cowen initiated coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They set a “market perform” rating for the company. Finally, Needham & Company LLC reissued a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and an average price target of $12.75.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of RXRX. ARK Investment Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 200.4% in the 4th quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company’s stock worth $203,651,000 after acquiring an additional 13,777,689 shares during the period. Mubadala Investment Co PJSC acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth approximately $128,041,000. Nvidia Corp acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter worth approximately $75,985,000. FMR LLC grew its holdings in shares of Recursion Pharmaceuticals by 134.4% in the 3rd quarter. FMR LLC now owns 10,689,532 shares of the company’s stock worth $81,775,000 after acquiring an additional 6,129,935 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Recursion Pharmaceuticals by 161.2% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company’s stock worth $90,749,000 after acquiring an additional 5,680,656 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.